Evidence map›Paper›PMID 40214452›Full record

ArticleCells2025

Therapeutic Potential of Emricasan, a Pan-Caspase Inhibitor, in Reducing Cell Death and Extracellular Matrix Accumulation in Fuchs Endothelial Corneal Dystrophy.

Sohya Fujimoto, Mako Endo, Shigehito Tonomura, Fuuga Tsuji, Hirotaka Haraguchi, Kanna Hasegawa, Taisuke Numao, Ayaka Izumi, Theofilos Tourtas, Ursula Schlötzer-Schrehardt and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sohya FujimotoDepartment of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 602-8580, Japan.
Mako EndoDepartment of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 602-8580, Japan.
Shigehito TonomuraDepartment of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 602-8580, Japan.
Fuuga TsujiDepartment of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 602-8580, Japan.
Hirotaka HaraguchiDepartment of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 602-8580, Japan.
Kanna HasegawaDepartment of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 602-8580, Japan.
Taisuke NumaoDepartment of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 602-8580, Japan.
Ayaka IzumiActualEyes Inc., Kyotanabe 610-0343, Japan.
Theofilos TourtasDepartment of Ophthalmology, University of Erlangen-Nürnberg, 430074 Erlangen, Germany.ORCID 0000-0002-3465-9837
Ursula Schlötzer-SchrehardtDepartment of Ophthalmology, University of Erlangen-Nürnberg, 430074 Erlangen, Germany.ORCID 0000-0001-8423-7395
Friedrich KruseDepartment of Ophthalmology, University of Erlangen-Nürnberg, 430074 Erlangen, Germany.
Yuki OyamaDepartment of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 602-8580, Japan.
Masahito IkawaGraduate School of Pharmaceutical Sciences, Osaka University, Suita 565-0871, Japan.ORCID 0000-0001-9859-6217
Albert S JunDepartment of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA 22903, USA.
Noriko KoizumiDepartment of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 602-8580, Japan.
Naoki OkumuraDepartment of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 602-8580, Japan.

Funding

JSPS 22K09824JSPS 24K12754
6 · The paper itself

Abstract

Fuchs endothelial corneal dystrophy (FECD) is a progressive disorder characterized by endothelial cell loss and excessive extracellular matrix (ECM) accumulation leading to corneal dysfunction. Emricasan, a pan-caspase inhibitor, was investigated for its therapeutic potential in suppressing these pathological changes. Patient-derived FECD cells and stress-induced cell models were treated with emricasan to assess its effects on apoptosis and ECM production. Caspase-specific knockdown experiments were performed to identify key mediators.

Indexed as

Caspase InhibitorsExtracellular MatrixFuchs' Endothelial DystrophyAnimalsApoptosisCell DeathDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLCaspase Inhibitorsanimal modelsapoptosiscaspase inhibitorcorneal endothelial cellsextracellular matrixFuchs endothelial corneal dystrophy

Identifiers

PMID40214452
PMCPMC11988121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.